Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Aseptika Develops Self-Monitoring, Home Lung Infection Test for People with CF

Published: Wednesday, June 26, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Company has announced that volunteers from Papworth Hospital NHS Foundation Trust are now participating in the clinical trial.

The trial incorporates the use of home telemetry to measure lung and cardiovascular function, levels of physical activity and body composition, which are combined with the measurement of biomarkers to predict the reoccurrence of chest infections.

This trial explores whether CF patients could self-monitor at home, with remote support from their clinicians, using the Company’s home infection test and the Activ8rlives web-based platform.

The Company successfully bid for and was awarded Phase 1 funding through NHS Midlands and East and the Health Enterprise East's second SBRI competition in 2011. In May of last year, Aseptika was also awarded Phase 2 funding to undertake this current study.

The company has already demonstrated the feasibility of quantifying the levels of key biomarkers in sputum samples as a way of predicting the onset of chest infections known clinically as 'exacerbations'. The biomarker tests can be used to give both clinicians and patients 7 to 10 days advanced warning of an exacerbation and when commercialised, could lead to a reduction in hospital admissions and length of stay, as well as improving healthcare outcomes for those with CF.

In the trial, volunteers measure key performance indicators of health such as Peak Flow, FEV1, pO2, heart rate, physical activity, weight, body composition, cough and wellness at home and this information is uploaded to their private Activ8rlives web account. The sputum profiling data is added to this same web database and correlated with the volunteer’s medication regime. This wealth of information can be viewed by the clinician for research purposes only at this stage during the trial, but will be made available to the patients at its completion.

In a comment on the current clinical trial, Dr. Anne Blackwood, Chief Executive of Health Enterprise East said, “Aseptika's technology platform has the potential to improve the quality of life of patients with CF in addition to reducing healthcare costs by preventing unnecessary admissions. Empowering patients to self-manage their condition is a key priority for the NHS.”

The objective of the self-monitoring solution being developed by Aseptika is to provide the tools to CF patients and their carers to help them stay well. Simultaneously this also provides their clinical team with complete, reliable and up to date information, especially for patients which have long journeys to attend their specialty clinics. Early changes in levels of biomarkers and health indicators will give patients, their families and clinicians every chance to identify when a course of treatment is becoming ineffective or when a change in treatment is required, or identify if additional support at home is needed.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos